Sorriso Pharmaceuticals Reports Positive Phase 1b Results for SOR102 in Ulcerative Colitis
Sorriso Pharmaceuticals, a biopharmaceutical company focused on developing novel oral antibodies for immune-mediated diseases, today announced positive results from its Phase 1b clinical trial of SOR102. This oral, dual-acting biologic targets TNFα and IL-23 and was tested in patients with…